FibroGen (NASDAQ:FGEN) Announces Earnings Results

FibroGen (NASDAQ:FGEN) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.09, Zacks reports. The company had revenue of $50.64 million for the quarter, compared to analysts’ expectations of $33.00 million. During the same period in the previous year, the firm posted ($0.65) earnings per share.

FibroGen Stock Up 4.5 %

FGEN stock traded up $0.02 during mid-day trading on Wednesday, reaching $0.46. 2,546,140 shares of the stock traded hands, compared to its average volume of 2,680,453. The business has a 50-day moving average of $1.00 and a two-hundred day moving average of $1.43. FibroGen has a 52 week low of $0.33 and a 52 week high of $2.93. The firm has a market capitalization of $45.76 million, a PE ratio of -0.18 and a beta of 0.71.

Analysts Set New Price Targets

Separately, William Blair reiterated a “market perform” rating on shares of FibroGen in a research note on Monday, June 3rd.

Insider Buying and Selling at FibroGen

In related news, insider Deyaa Adib purchased 22,123 shares of FibroGen stock in a transaction on Wednesday, June 12th. The stock was purchased at an average cost of $1.17 per share, with a total value of $25,883.91. Following the acquisition, the insider now directly owns 82,123 shares in the company, valued at $96,083.91. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 1.98% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.